Charles (‘Chuck’) Wilson is President and Chief Executive Officer of Unum Therapeutics, a company developing a novel cellular immunotherapy platform for the treatment of cancer.

Immediately prior to starting Unum, Chuck served as Vice President, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research (NIBR), the research and early development division of Novartis.  In this role he was responsible for leading partnering efforts to support Novartis across all disease areas up through clinical proof-of-concept.  His efforts included academic and biotech collaborations, equity investing in early stage companies, in-licensing of compounds, and spin-out of assets/technologies to start ups.

Prior to joining Novartis, Chuck co-founded Archemix, a Cambridge, MA biotech company focused on the development of aptamers as therapeutics.  At Archemix, Chuck served as Chief Technology Officer, responsible for both developing the company’s technology platform and managing its drug discovery efforts.  As part of the senior management team, Chuck helped the company raise over $100 million in equity financing and grow to approximately 100 employees, advancing multiple programs into clinical development in the process.

Before moving into industry, Chuck was a professor in the Markey Center for the Molecular Biology of RNA at the University of California, Santa Cruz.  There he determined the first x-ray crystal structures of RNA aptamers bound to their targets and developed such molecules as tools for regulating gene expression.  Trained in structural biology and molecular biology, Chuck received his PhD with David Agard (UCSF, HHMI) and did his postdoctoral training with Nobelist Jack Szostak (Havard University / Massachusetts General Hospital).